Brought to you by 
Valeant proposes to buy Allergan for $45bn in cash and stock; ups offer to $53bn; Actavis offers $66bn, winning takeover battle
01 Jun 2021
Executive Summary
In a deal that would create the global leader in ophthalmology, dermatology, and aesthetics, Valeant Pharmaceuticals International Inc. proposed to pay $45.1bn for Allergan Inc., whose stockholders would receive $48.30 per share in cash and 0.83 Valeant shares for each share held (worth $152.89, a 22% premium).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash for Equity
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant proposes to buy Allergan for $45bn in cash and stock; ups offer to $53bn; Actavis offers $66bn, winning takeover battle
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice